These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36867758)

  • 1. THE EUROPEAN SHOCK SOCIETY MEETS THE IMMUNOSEP CONSORTIUM FOR PERSONALIZED SEPSIS TREATMENT.
    Giamarellos-Bourboulis EJ; Dimopoulos G; Flohé S; Kotsaki A; van der Poll T; Skirecki T; Torres A; Netea MG
    Shock; 2023 Mar; 59(3S Suppl 1):21-25. PubMed ID: 36867758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol.
    Kotsaki A; Pickkers P; Bauer M; Calandra T; Lupse M; Wiersinga WJ; Meylan S; Bloos F; van der Poll T; Slim MA; van Mourik N; Müller MCA; van Vught L; Vlaar APJ; de Nooijer A; Bakkerus L; Weis S; Antonakos N; Netea MG; Giamarellos-Bourboulis EJ
    BMJ Open; 2022 Dec; 12(12):e067251. PubMed ID: 36600424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.
    Shakoory B; Carcillo JA; Chatham WW; Amdur RL; Zhao H; Dinarello CA; Cron RQ; Opal SM
    Crit Care Med; 2016 Feb; 44(2):275-81. PubMed ID: 26584195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial.
    Leventogiannis K; Kyriazopoulou E; Antonakos N; Kotsaki A; Tsangaris I; Markopoulou D; Grondman I; Rovina N; Theodorou V; Antoniadou E; Koutsodimitropoulos I; Dalekos G; Vlachogianni G; Akinosoglou K; Koulouras V; Komnos A; Kontopoulou T; Prekates A; Koutsoukou A; van der Meer JWM; Dimopoulos G; Kyprianou M; Netea MG; Giamarellos-Bourboulis EJ
    Cell Rep Med; 2022 Nov; 3(11):100817. PubMed ID: 36384100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
    Opal SM; Fisher CJ; Dhainaut JF; Vincent JL; Brase R; Lowry SF; Sadoff JC; Slotman GJ; Levy H; Balk RA; Shelly MP; Pribble JP; LaBrecque JF; Lookabaugh J; Donovan H; Dubin H; Baughman R; Norman J; DeMaria E; Matzel K; Abraham E; Seneff M
    Crit Care Med; 1997 Jul; 25(7):1115-24. PubMed ID: 9233735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine with IgGAM compared with standard of care for treatment of peritonitis after infectious source control (the PEPPER trial): study protocol for a randomized controlled trial.
    Kalvelage C; Zacharowski K; Bauhofer A; Gockel U; Adamzik M; Nierhaus A; Kujath P; Eckmann C; Pletz MW; Bracht H; Simon TP; Winkler M; Kindgen-Milles D; Albertsmeier M; Weigand M; Ellger B; Ragaller M; Ullrich R; Marx G
    Trials; 2019 Mar; 20(1):156. PubMed ID: 30832742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*.
    Rajasekaran S; Kruse K; Kovey K; Davis AT; Hassan NE; Ndika AN; Zuiderveen S; Birmingham J
    Pediatr Crit Care Med; 2014 Jun; 15(5):401-8. PubMed ID: 24583503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series.
    Payen D; Faivre V; Miatello J; Leentjens J; Brumpt C; Tissières P; Dupuis C; Pickkers P; Lukaszewicz AC
    BMC Infect Dis; 2019 Nov; 19(1):931. PubMed ID: 31690258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sepsis Care Pathway 2019.
    Labib A
    Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
    Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
    Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases.
    Rello J; van Engelen TSR; Alp E; Calandra T; Cattoir V; Kern WV; Netea MG; Nseir S; Opal SM; van de Veerdonk FL; Wilcox MH; Wiersinga WJ
    Clin Microbiol Infect; 2018 Dec; 24(12):1264-1272. PubMed ID: 29581049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision Immunotherapy for Sepsis.
    Peters van Ton AM; Kox M; Abdo WF; Pickkers P
    Front Immunol; 2018; 9():1926. PubMed ID: 30233566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.
    Patil NK; Bohannon JK; Sherwood ER
    Pharmacol Res; 2016 Sep; 111():688-702. PubMed ID: 27468649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunomodulation for sepsis: a change of tack?].
    Leentjens J; Kox M; Pickkers P
    Ned Tijdschr Geneeskd; 2014; 158():A6859. PubMed ID: 24518844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New frontiers in precision medicine for sepsis-induced immunoparalysis.
    Bruse N; Leijte GP; Pickkers P; Kox M
    Expert Rev Clin Immunol; 2019 Mar; 15(3):251-263. PubMed ID: 30572728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis.
    Karakike E; Giamarellos-Bourboulis EJ
    Front Immunol; 2019; 10():55. PubMed ID: 30766533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial)-study protocol for a randomized, controlled, interventional, open-label, multicenter trial.
    Brenner T; Skarabis A; Stevens P; Axnick J; Haug P; Grumaz S; Bruckner T; Luntz S; Witzke O; Pletz MW; Ruprecht TM; Marschall U; Altin S; Greiner W; Berger MM;
    Trials; 2021 Oct; 22(1):714. PubMed ID: 34663439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.